DFO
GPCR icon

Duquesne Family Office’s Structure Therapeutics GPCR Stock Holding History

Duquesne Family Office’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,700
Closed -$1.48M – 83
2024
Q2 		$1.48M Buy
+37,700
New +$1.55M 0.05% 59

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Duquesne Family Office's GPCR Position: Q3 2024 in Review

Duquesne Family Office sold out of Structure Therapeutics (GPCR) in Q3 2024, closing a stake of 37,700 shares — an estimated $1.48M sold.

Duquesne Family Office first reported a position in GPCR in Q2 2024 and held it in 1 quarter. The position peaked at $1.48M in Q2 2024. 160 funds tracked by Wall St. Rank hold GPCR as of Q3 2024.

  • Duquesne Family Office reported no remaining Structure Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Duquesne Family Office sold 37,700 Structure Therapeutics shares in Q3 2024, an estimated $1.48M.
  • Duquesne Family Office first reported a position in Structure Therapeutics in Q2 2024 and held it in 1 quarter.
  • Duquesne Family Office's Structure Therapeutics position peaked at $1.48M in Q2 2024.
  • 160 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2024.

Based on Duquesne Family Office's 13F filing for Q3 2024, filed 14 Nov 2024.